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Background: Gastrointestinal (GI) manifestations are common in autistic children. Polyunsaturated fatty acids
(PUFAs) and carnitine are anti-inflammatory molecules and their deficiency may result in GI inflammation. The
relationship between the increased frequency of GI manifestations and reduced levels of PUFAs and carnitine was
not previously investigated in autistic patients. This study was the first to investigate plasma levels of PUFAs and
serum carnitine in relation to GI manifestations in autistic children.
Methods: Plasma levels of PUFAs (including linoleic, alphalinolenic, arachidonic “AA” and docosahexaenoic “DHA”
acids) and serum carnitine were measured in 100 autistic children and 100 healthy-matched children.
Results: Reduced levels of serum carnitine and plasma DHA, AA, linolenic and linoleic acids were found in 66%,
62%, 60%, 43% and 38%, respectively of autistic children. On the other hand, 54% of autistic patients had elevated
ω6/ω3 ratio. Autistic patients with GI manifestations (48%) had significantly decreased levels of serum carnitine and
plasma DHA than patients without such manifestations. In addition, autistic patients with GI manifestations had
significantly increased percentage of reduced serum carnitine (91.7%) and plasma DHA levels (87.5%) than patients
without such manifestations (42.3% and 38.5%, respectively), (P < 0.001 and P < 0.001%, respectively).
Conclusions: Reduced levels of plasma DHA and serum carnitine levels may be associated with the GI problems in
some autistic patients. However, this is an initial report, studies are recommended to invesigate whether reduced
levels of carnitine and DHA are a mere association or have a pathogenic role in GI problems in autistic patients.
Keywords: Autism, Brain energy, Carnitine, Docosahexaenoic acid, Gastrointestinal manifestations, Polyunsaturated
fatty acidsBackground
Some cases of autism may be associated with several or-
ganic conditions including disturbance of brain energy
metabolism which depends on adequate supply of polyun-
saturated fatty acids (PUFAs) and carnitine and normal
mitochondrial function [1,2]. Fatty acids are key nutrients
that affect early growth and development. Among the fatty
acids, omega-3 polyunsaturated fatty acids (n-3 PUFA)
and omega-6 PUFA (n-6 PUFA) which have been suggested* Correspondence: gehan.mostafa2000@yahoo.com
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article, unless otherwise stated.to decrease and increase the severity of several human dis-
eases, respectively. PUFA are long-chained and unsatur-
ated molecules only obtained by dietary intake of certain
grains such as flaxseed and canola, walnuts, and sea fish.
PUFA that contain more than one carbon- carbon double
bond are classified into n-6 and n-3 fatty acids that have,
in common, a final carbon-carbon double bond in the n-3
(n-3 PUFA) or n-6 (n-3 PUFA) position, counting from
the methyl end. The numeric designations used for PUFA
is derived from the number of carbon atoms, followed by
the number of sites of unsaturation. Linoleic acid (LA)
is the shortest-chained omega − 6 fatty acid serving as a
substrate that can be converted to arachidonic acid
(AA) which is an important omega − 6 fatty as it is the
precursor for prostaglandins [3]. α-linolenic acid (ALA),d Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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(DHA) are important n-3 PUFA contributing to either
achieving optimal health or protection against diseases,
and even longevity. Human brain is 60% fat of which
25% is DHA [4,5].
The optimal range of the ratio of omega6/omega3
(AA/DHA) varies from 1/1 to 4/1. High ω6/ω3 ratio
promotes the pathogenesis of many diseases. Whereas
low ω6/ω3 ratio exerts a suppressive effect. A ratio of
ω6/ω3 of 4/1 is the optimal ratio of brain mediated func-
tion [6]. PUFAs are needed for normal brain develop-
ment and function as PUFAs modulate the function of
many neurotransmitters, membrane fluidity, intracellular
Ca(2+) signaling and hence function of the neuronal cell
[5]. The role of (n-3) fatty acids in controlling inflamma-
tion and protecting neuron cells from oxidative damage
has been reported, so they could be beneficial in treat-
ment of some psychiatric illnesses [7]. Carnitine, a nutri-
ent synthesized in the liver and kidney, is essential for
transport of long chain fatty acids across inner mitochon-
drial membrane for β- oxidation and energy production.
Synaptic transmission of multiple neurotransmitters needs
the neurobiological effect of acetyl carnitine [8].
Gastrointestinal (GI) disturbances such as abdominal
pain, chronic diarrhea, constipation, vomiting, gastro-
esophageal reflux, and intestinal infections.are commonly
reported in children with autism, and may contribute to
behavioral impairment [9,10]. Reports of deficiencies in di-
saccharidase enzymatic activity and of beneficial responses
to probiotic and dietary therapies led researchers to survey
gene expression and the mucoepithelial microbiota in in-
testinal biopsies from children with autism. Autistic chil-
dren can benefit from adaptation of general pediatric
guidelines for the diagnostic evaluation of abdominal pain,
chronic constipation, and gastroesophageal reflux disease
[11]. Carnitine and PUFAs are anti-inflammatory mole-
cules and their deficiency may result in GI inflammation
and gut injury [12,13]. Patients with chronic intestinal dis-
ease should be evaluated for likely PUFAs deficiencies and
imbalances, and treated with substantial amounts of sup-
plements rich in PUFAs, such as oral vegetable and fish
oils, or intravenous lipids if necessary [14].
The relationship between the increased frequency of
GI manifestations and reduced levels of PUFAs and car-
nitine was not previously investigated in autistic patients.
This study was the first to investigate plasma levels of
PUFAs and serum carnitine in relation to GI manifesta-
tions in autistic children. This may add new biological
indices and therapeutic implications for autism.
Methods
Study population
This cross-sectional study was conducted on 100 chil-
dren with autism. They were recruited from the AutismResearch and Treatment Center, Faculty of Medicine,
King Saud University, Riyadh, Saudi Arabia. Patients
were fulfilling the criteria of the diagnosis of autism ac-
cording to the 4th edition of the Diagnostic and Statis-
tical Manual of Mental Disorders [15]. The autistic
group comprised 78 males and 22 females. Their ages
ranged between 3 and 10 years (mean ± SD = 6.22 ±
2.1 years). Patients who had associated neurological dis-
eases (such as cerebral palsy and tuberous sclerosis) and
metabolic disorders (eg. Phenylketonuria) were excluded
form the study. Also, autistic patients on PUFAs or anti-
convulsants therapy were not included.
The control group comprised 100 age- and sex-
matched apparently healthy children They included 78
males and 22 females. They were the healthy older sib-
lings of the healthy infants who attend the Well Baby
Clinic, King Khalid University Hospital, Faculty of
Medicine, King Saud University, Riyadh, Saudi Arabia
for routine following-up of their growth parameters.
The control children were not related to the children
with autism, and demonstrated no clinical findings
suggestive of immunological, GI or neuropsychiatric
disorders. Their ages ranged between 3 and 10 years
(mean ± SD = 5.96 ± 2 years).
None of the studied subjects was vegetarian or was on
a restricted diet such as casein and guten-free diet. All
studied subjects had normal body weight (body mass
index (BMI) was between the fifth and less than the
85th percentiles based on age and sex). Also, none of the
studied subjects had abnormal results of stool analysis.
The local Ethical Committee of the Faculty of Medicine,
King Saud University, Riyadh, Saudi Arabia, approved this
study. In addition, an informed written consent of partici-
pation in the study was signed by the parents or the legal
guardians of the studied subjects.
Study measurements
Clinical evaluation of autistic patients
This was based on clinical history taking from caregivers,
clinical examination and neuropsychiatric assessment.
Gastrointestinal symptoms were assessed with the parent-
report version of the Questionnaire on Pediatric Gastro-
intestinal Symptoms by an experienced pediatric gastro-
enterologist according to the Questionnaire on Pediatric
Gastrointestinal Symptoms - Rome III Version used by
previous studies that assessed gastrointestinal dysfunction
in autism [16]. In addition, stool analysis was done for all
patients.
The degree of the disease severity was assessed by
using the Childhood Autism Rating Scale (CARS) [17]
which rates the child on a scale from one to four in each
of fifteen areas (relating to people; emotional response;
imitation; body use; object use; listening response; fear
or nervousness; verbal communication; non-verbal
Table 1 Plasma PUFAs and serum carnitine levels in








Serum carnitine (mg/ml) 3.3 (2) 7.2 (2.6) < 0.001
Plasma DHA (ω3) (μg/ml) 0.18 (1.2) 3.1 (0.8) < 0.001
Plasma linolenic (μg/ml) 1.6 (1.3) 3.3 (2.6) <0.01
Plasma AA (ω6) (μg/ml) 1.7 (1.8) 4.2 (3.4) <0.01
Plasma linoleic (μg/ml) 1.3 (2.6) 3.2 (1.5) <0.05
ω6/ω3 3 (2.4) 1.8 (1.4) <0.01
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intellectual response; adaptation to change; visual re-
sponse; taste, smell and touch response and general
impressions). According to the scale, children who
have scored 30–36 have mild to moderate autism (n = 38),
while those with scores ranging between 37 and 60 points
have a severe degree of autism (n = 62).
Samples collection
Blood samples were collected in the morning following
at least 10 hour period of fasting. Blood samples were
equally subdivided into two clean tubes, the first tube
was dry and the blood was left to clot, then the serum
was separated and stored at −20°C until assay of carni-
tine. The second tube was containing fluoride EDTA as
an anticoagulant, then centrifugation of the samples was
done immediately and plasma was separated and stored
in sterile aliquoutes at −80°C until assay of PUFAs.
Assessment of serum carnitine
Serum carnitine was measured by using enzymatic ultra-
violet test from Roche Diagnostics Gmbh, Cat. No. 1′
242008, Germany [18]. To increase accuracy, all samples
were analyzed twice in two independent experiments to
assess inter-assay variations and to ensure reproducibility
of the observed results (P > 0.05). No significant cross-
reactivity or interference was observed.
Determination of plasma polyunsaturated fatty acids
(Linoleic, Linolenic, Arachidonic and Docosahexaeinoic
acids)
The principle was the injection of separated fatty acids
from the plasma into the gas chromatography instru-
ment. Separation of fatty acids from plasma was done by
addition of 3 ml of 3 g/L solution of nonanoic acid in
100 μL of acetyl chloride slowly with magnetic strirring
for 45 min at room temperature. Three ml of 6% potas-
sium carbonate solution was added in water with stiring
while cooling the mixture in an ice bath. After that,
300 μL of hexan and vortex were added and the sample
was cooled at 4°c for 30 minutes. Then, centrifugation
was done for 10 minutes. Finally, 100 μ of the upper
layer was removed and 1.1 μL was subjected to Gas
Chromatography H5890 (Hewlett-Pakard, Palo Alto,
CA) [19]. To increase accuracy, all samples were analyzed
twice in two independent experiments to assess inter-
assay variations and to ensure reproducibility of the ob-
served results (P > 0.05). No significant cross-reactivity
or interference was observed.
Statistical analysis
The results were analyzed by the commercially available
software package (Statview, Abacus concepts, inc., Berkley,
CA). The data was non-parametric and was presented asmedian and interquartile range (IQR), which is the dif-
ference between the 75th and 25th percentiles. Mann–
Whitney U-test was used for comparison of data.
Chi-square test was used for comparison between quali-
tative variables of the studied groups. Spearman’s rho
correlation coefficient “r” was used to determine the re-
lationship between different variables. For all tests, a
probability (P) of less than 0.05 was considered signifi-
cant. As data distribution was non-parametric, patients
were considered to have decreased serum carnitine,
plasma DHA, linolenic, arachidonic and linoleic acids if
their levels were below the 5th percentile of the control
values (4.96 mg/ml, 1.35 μg/ml, 1.56 μg/ml, 2.64 μg/ml,
and 1.38 μg/ml respectively). On the other hand, pa-
tients were considered to have elevated ω6/ω3 ratio if
their levels were above the 95th percentile of the control
values (3.84).
Results
Plasma PUFAs and serum carnitine levels in autistic
children
Autistic patients had significantly lower levels of plasma
PUFAs and serum carnitine than healthy children. On
the other hand, ω6/w3 ratio (AA/DHA) was significantly
higher in autistic patients than healthy children (Table 1).
Low serum carnitine and plasma DHA, AA, linolenic
and linoleic acids, below the 5th percentile of the control
values, were found in 66%, 62%, 60%, 43% and 38%, re-
spectively of autistic children. On the other hand, 54% of
autistic patients had elevated ω6/ω3 ratio above the 95th
percentile of the control values.
There was a significant positive association between
the reduced serum levels of carnitine and the elevated
ω6/w3 ratio in autistic children as the percentage of ele-
vated ω6/w3 was significantly higher in autistic patients
with reduced serum levels of carnitine (94.7%) than
patients with normal serum carnitine levels (48.4%)),
P < 0.001.
Plasma levels of PUFAs and serum levels of carnitine
had no significant correlations with CARS and the age
of autistic children (P > 0.05). Also, plasma levels of PUFAs
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levels (P > 0.05).
Relationship between gastrointestinal manifestations and
both plasma PUFAs and serum carnitine levels in autistic
children
Gastrointestinal manifestations were found in 48 autistic
children (48%). They include recurrent unexplained at-
tacks of epigastric pain and chromic constipation in 20
patients, chronic constipation and bloating in 22 patients
and recurrent attacks of diarrhea, with normal results of
stool analysis, in 6 patients. These symptoms were re-
ported by the parents of autistic children. They were re-
current, severe and the patients were attending the
clinic because of these agonizing symptoms. None of the
autistic children had abnormal results of stool analysis.
Autistic patients with GI manifestations had signifi-
cantly lower serum carnitine and plasma DHA than pa-
tients without such manifestations. On the other hand,
ω6/w3 ratio was significantly higher in autistic patients
with GI problems than patients without such manifesta-
tions (Table 2).
Autistic patients with GI manifestations had signifi-
cantly higher percentage of reduced serum carnitine
(91.7%) and plasma DHA levels (87.5%) than patients
without such manifestations (42.3% and 38.5%, respect-
ively), (P < 0.001 and P < 0.001%, respectively). On the
other hand, autistic patients with GI manifestations had
significantly higher percentage of elevated ω6/w3 ratio
(62.5%) than patients without such manifestations
(15.4%), P < 0.001.
Discussion
In the current study, autistic patients had significantly
lower levels of plasma PUFAs than healthy children. OnTable 2 Plasma PUFAs and serum carnitine levels in
autistic patients with and without GI manifestations
Autistic patients with
GI manifestations








2.3 (2.2) 5 (3) < 0.001
Plasma DHA
(ω3) (μg/ml)
0.12 (1) 2.2 (0.9) < 0.001
Plasma
linolenic (μg/ml)
1.2 (1.3) 2 (2) >0.05
Plasma AA
(ω6) (μg/ml)
1.1 (1.6) 1.8 (3.4) >0.05
Plasma
linoleic (μg/ml)
1.2 (3) 2 (2.5) >0.05
ω6/ω3 4.8 (1.6) 2.5 (1.4) <0.01the other hand, ω6/w3 ratio (AA/DHA) was significantly
higher in autistic patients than healthy children. One
preliminary study found that average total levels of
omega-3 (n-3 PUFAs) in the autistic children were about
20% lower than mentally retarded children used as con-
trols. Levels of DHA were 23% lower. These deficiencies
resulted in a significantly higher ratio of n-6 to n-3 in
25% of autistic children [20]. It is widely accepted that
the PUFAs have an important role in many neural path-
ways and that their deficiency may be correlated with
the occurrence of several psychiatric illnesses such as
major depression, attention-deficit hyperactivity disor-
ders, dyslexia, dyspraxia and autism and they are fea-
tured as adjunctive or as monotherapy for treatment of
these diseases with many surprising results [7,21,22]. Al-
though no definite conclusions can be drawn on the
therapeutic efficacy of omegs-3 PUFAs in some psychi-
atric diseases, the evidence suggests that these molecules
have a potential preventive role in people at extremely
high risk for developing psychosis [23].
The mechanisms by which DHA can impact on neur-
onal functions involve the modulation of membrane bio-
physical properties, the regulation of neurotransmitter
release (such as dopamine and serotonin), the synthesis
of oxygenated biologically active derivatives, and the nu-
clear receptor mediated transcription of lipid responsive
genes [24]. Some studies of human infants suggest that
dietary DHA may play a role in cognitive development
and in some neurodevelopmental disorders like autism
[25]. Placebo-based studies established the appropriate
therapeutic dose of (n-3) fatty acids, varying from the
recommended dietary dose to an amount that may be 3
or 4 times higher. Amminger et al. [26] conducted a
pilot trial with 13 autistic children for 6 wk in which
1.5 g (n-3) fatty acid composition were given. They ob-
served a statistically significant change in hyperactivity
and stereotypy of behavior in autistic children compared
with the placebo group. On the other hand, the effect of
omega-3 FA supplementation in adults with autism may
not be beneficial as one study reported no significant
improvement of behavioral abnormalities after omega-3
FA supplementation in adults with severe autism [27].
The current study revealed lower levels of serum car-
nitine in autistic patients than healthy children. A previ-
ous study also reported carnitine deficiency in a group
of autistic children. Acetyl carnitine is needed for mito-
chondrial transfere of PUFAs and synaptic transmission
of multiple neurotransmitters which affect attention,
antagonize deterioration of ability to learn and improve
long term memory. Carnitine has been proposed to be a
conditionally essential nutrient, and even termed vitamin
BT. Carnitine homeostasis in humans is maintained by a
modest rate of endogenous synthesis, absorption from
dietary sources, and efficient tubular reabsorption by the
Mostafa and AL-Ayadhi Behavioral and Brain Functions  (2015) 11:4 Page 5 of 7kidney [28]. Carnitine deficiency can develop secondary
to dietary inadequacy or as an adverse effect of medical
treatment secondary to administration of pivalate-
conjugated antibiotics or valproic acid [29]. A deletion
of the 6-N-trimethyllysine dioxygenase gene, the first en-
zyme of the carnitine biosynthesis pathway in mitochon-
dria, was discovered while studying probands with
autism [30]. Mitochondrial defect which is the most
common metabolic abnormality associated with autism
may be the origin of carnitine deficiency in some autistic
children. Several studies suggested that nutritional sup-
plements may be beneficial in some children with autism
who have mitochondrial dysfunction or abnormal bio-
markers of mitochondrial function. Carnitine was the
most commonly noted supplement to be helpful [31,32].
Anhedonia is a condition in which the capacity of ex-
periencing pleasure is totally or partially lost and it was
reported in various psychiatric disorders [33]. Selective
social anhedonia was reported in autism [34]. The use of
acetyl-l-carnitine to treat anhedonia, melancholic, and
negative symptoms in anhedonic alcoholics was pro-
posed [35] due to the effect of acetyl-l-carnitine on
dopamine outflow, which is mostly implicated in anhe-
donia, alcohol and substance use disorders. Carnitine
supplementation has been shown to significantly in-
crease the levels of dopamine in the cortex, hippocam-
pus, and striatum of rat brain [36]. Martinotti et al.
(2011) reported the efficacy and safety of acetyl-l-
carnitine in the treatment of anhedonia, melancholia,
and negative symptoms in anhedonic alcoholics after
10 days of intravenous therapy [37]. Acetyl-l-carnitine
was also reported to be effective in the treatment of
non-alcoholic fatty liver disease [38]. L-carnitine therapy
(50 mg/kilogram-bodyweight/day) administered for
3-months significantly improved several clinical mea-
surements of ASD severity [1], but subsequent stud-
ies are recommended.
In the present work, GI manifestations (recurrent un-
explained attacks of epigastric pain, chromic constipa-
tion, bloating and recurrent attacks of diarrhea, with
normal results of stool analysis) were found in 48%.of
autistic patients. The reported prevalence of GI abnor-
malities in autism is high [11]. A previous research re-
ported that the majority (61%) of children had at least
one reported gastrointestinal symptom [39]. In this
study, 91.7% of autistic patients with GI manifestations
had chronic constipation which was reported to be the
most common type of GI dysfunction in children with
autism (85%). As children with autism can benefit from
adaptation of general pediatric guidelines for the diag-
nostic evaluation of GI problems [11], this should be
addressed in future studies. In addition, this study
depended on clinical manifestations and stool analysis
for detection of gastrointestinal dysfunction in autisticchildren Thus, investigations such as stool bacteriology,
GI endoscopy and biopsy should be performed in future
studies for better evaluation of GI problems in autistic
children.
How GI factors are related to autism is not yet clear.
Many patients with autism have a history of previous
antibiotic exposure, GI symptoms, abnormal food crav-
ings, and unique intestinal bacterial populations, which
have been proposed to relate to variable symptom sever-
ity [40]. Recent evidence suggests potential, but un-
proven, links between dietary, metabolic, infective, and
gastrointestinal factors and the behavioral exacerbations
and remissions of autism. Propionic acid and its related
short-chain fatty acids (SCFAs) are fermentation products
of autism-associated bacteria (Clostridia, Bacteriodetes,
Desulfovibrio). SCFAs represent a group of compounds
derived from the host microbiome that are plausibly
linked to autism and can induce widespread effects on
gut, brain, and behavior [41]. The strong correlation of GI
symptoms with autism severity indicates that children
with more severe autism are likely to have more severe
gastrointestinal symptoms and vice versa. The low level of
SCFA’s was partly associated with increased probiotic use,
and probably due to either lower production and/or
greater absorption. Percentage DNA damage, tail length,
and tail moment are adequate biomarkers of propionic
acid neurotoxicity due to oral administration or as a me-
tabolite of induced enteric bacterial overgrowth [42].
In this work, autistic patients with GI manifestations
had significantly lower serum carnitine and plasma DHA
than patients without such manifestations. These results
may demonstrate the possible association between GI
manifestations and the reduced levels of serum carnitine
and plasma DHA in autistic patients. The relationship
between GI manifestations and plasma levels of PUFAs
and serum carnitine in autistic children was not previ-
ously investigated.
All varieties of (n-3) acids (mainly alpha-linoleic, DHA,
and EPA) are essential components in mammalian metab-
olism, whether they act as anti-inflammatory molecules,
immune-modulating agents, and the main components in
guaranteeing cell membrane stability [12]. PUFAs are
known to modulate inflammation. Preoperative parenteral
PUFA-LE supplementation, preferably by marine (n-3)
PUFA, ameliorates postoperative intestinal inflammation
and dysmotility [43]. Carnitine’s role in the GI tract has
recently been highlighted by several publications linking
mutations in genes encoding carnitine transporters OCTN1
(SLC22A4) and OCTN2 (SLC22A5) with Crohn’s disease
[44]. Carnitine plays a major role in neonatal mouse gut
development and differentiation, and carnitine deficiency
leads to increased apoptosis of enterocytes, villous atro-
phy, inflammation and gut injury. Carnitine deficiency led
to increased expression of CD45-B220+ lymphocytes with
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pro-inflammatory cytokines in immune cells [13].
L-carnitine administered prior to the irradiation reduced
the severity of intestinal mucosal damage as treatment
with L-carnitine decreased the serum MCP-1 and IFN-γ
levels considerably [45].
This work may denote a possible association between
GI manifestations and the reduced levels of serum carni-
tine and plasma DHA in autistic patients as a result of
the decrease of their anti-inflammatory effects. It is not
evident if GI manifestations are mere association or con-
sequence to reduced PUFAs and carnitine levels in these
patients. Further investigations are recommended, with a
larger subject population, to determine the possible
pathogenic role of the deficiency of PUFAs and carnitine
levels in the occurrence of GI manifestations in autistic
patients.
Conclusions
Some autistic children have reduced levels of plasma
PUFAs and serum carnitine which may be associated to
GI manifestations in these patients. However, these data
should be treated with caution until further investiga-
tions are performed, with a larger subject population, to
determine whether the occurrence of GI manifestations
is a mere association or a consequence to reduced plasma
PUFAs and serum carnitine levels in autistic patients.
Studies looking at a potential role of PUFAs and carnitine
in treatment of autism and amelioration of GI problems
are recommended.
Abbreviations
AA: Arachidonic acid; ALA: α-linolenic acid; CARS: Childhood Autism Rating
Scale; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid;
GI: Gastrointestinal; IQR: Interquartile range; LA: Linoleic acid;
PUFAs: Polyunsaturated fatty acids; SCFAs: Short-chain fatty acids.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Both authors designed, performed and wrote the research. In addition, both
authors read and approved the final manuscript.
Authors’ information
All coauthors have seen and agree with the contents of the manuscript.
Submission is not under review at any other publication. We have no
financial or commercial involvement or other conflicts of interest by any
author.
Acknowledgements
This research project was supported by a grant from the Research Center of
the Center for Female Scientific and Medical Colleges in King Saud
University.
Received: 18 August 2014 Accepted: 28 December 2014
References
1. Geier DA, Kern JK, Davis G, King PG, Adams JB, Young JL, et al. A
prospective double-blind, randomized clinical trial of levocarnitine to treat
autism spectrum disorders. Med Sci Monit. 2011;17:I15–I123.2. Legido A, Jethva R, Goldenthal MJ. Mitochondrial dysfunction in autism.
Semin Pediatr Neurol. 2013;20(3):163–75.
3. Burlingame B, Nishida C, Uauy R, Weisell R. Fats and fatty acids in human
nutrition: introduction. Ann Nutr Metab. 2009;55:5–7.
4. Park JM, Kwon SH, Han YM, Hahm KB, Kim EH. Omega-3 polyunsaturated
Fatty acids as potential chemopreventive agent for gastrointestinal cancer.
J Cancer Prev. 2013;18(3):201–8.
5. Innis SM. The role of dietary n-6 and n-3 fatty acids in the developing brain.
Dev Neurosci. 2000;22:474–80.
6. Simopoulos AP. Importance of the ratio of omega-6/ omega-3 essential
fatty acids. Biomed Pharmacother. 2002;56:365–79.
7. Prior PL. JcF. (N-3) Fatty Acids: Molecular Role and Clinical Uses in
Psychiatric Disorders. Adv Nutr. 2012;3:257–65.
8. Virmani A, Gaetani F, Imam S, Binienda Z, Ali S. The protective role of
L-carnitine against neurotoxicity evoked by drug of abuse,
methamphetamine, could be related to mitochondrial dysfunction.
Ann N Y Acad Sci. 2002;965:225–32.
9. Douglas-Escobar M, Elliott E, Neu J. Effect of intestinal microbial ecology on
the developing brain. JAMA Pediatr. 2013;167:374–9.
10. Samsam M, Ahangari R, Naser SA. Pathophysiology of autism spectrum
disorders: Revisiting gastrointestinal involvement and immune imbalance.
World J Gastroenterol. 2014;20(29):9942–51.
11. Buie T, Fuchs III GJ, Furuta GT, Kooros K, Levy J, Lewis JD, et al. Recommendations
for evaluation and treatment of common gastrointestinal problems in children
with ASDs. Pediatrics. 2010;125(1):S19–29.
12. Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the
anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev.
2010;68:280–9.
13. Sonne S, Shekhawat PS, Matern D, Ganapathy V, Ignatowicz L. Carnitine
deficiency in OCTN2-/- newborn mice leads to a severe gut and immune
phenotype with widespread atrophy, apoptosis and a pro-inflammatory
response. PLoS ONE. 2012;7:e47729.
14. Siguel EN, Lerman RH. Prevalence of essential fatty acid deficiency in patients
with chronic gastrointestinal disorders. Metabolism. 1996;45(1):12–23.
15. American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders. 4th ed. Washington DC: American Psychiatric Association;
1994.
16. Gorrindo P, Williams KC, Lee EB, Walker LS, McGrew SG, Levitt P.
Gastrointestinal dysfunction in autism: parental report, clinical evaluation,
and associated factors. Autism Res. 2012;5(2):101–8.
17. Schopler E, Reichler RJ, Renner BR. The Childhood Autism Rating Scale
(CARS), for Diagnostic Screening and Classification in Autism; New York. NY:
Irvington; 1986.
18. Wieland OH. Determination of plasma carnitine by enzymatic ultraviolet
test. In: Bergermeyer HU, editor. Methods of Enzymatic Analysis. 3rd ed.
Florida: VCH Verlagsgesellschaft, weinheim, Deerfield Beach; 1965. p. 481–8.
19. Onkenhout W, Venizelos V, van der Poel PF, van den Heuvel MP, Poorthuis
BJ. Identification and quantification of intermediates of unsaturated fatty
acids metabolism in plasma of patients with fatty acids oxidation disorder.
Clin Chem. 1995;41:1467–74.
20. Vancassel S, Durand G, Barthélémy C, Lejeune B, Martineau J, Guilloteau D,
et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot
Essent Fatty Acids. 2001;65(1):1–7.
21. Hibbeln JR. Fish consumption and major depression. Lancet. 1998;351:1213.
22. Richardson AJ, Ross MA. Fatty acid metabolism in neurodevelopmental
disorders: a new perspective on associations between attention-deficit
hyperactivity disorders, dyslexia, dyspraxia and the autistic spectrum. Prosta-
glandins Leukot Essent Fatty Acids. 2000;63:1–9.
23. Politi P, Rocchetti M, Emanuele E, Rondanelli M, Barale F. Randomized
placebo-controlled trials of omega-3 polyunsaturated fatty acids in psychiatric
disorders: a review of the current literature. Curr Drug Discov Technol. 2013;10
(3):2452–3.
24. Alessandri JM, Guesnet P, Vancassel V, Astorg P, Denis I, Langelier B, et al.
Polyunsaturated fatty acids in the nervous system: evolution of concepts and
nutritional implications throughout life. Reprod Nutr Dev. 2004;44:509–38.
25. Wainwright PE. Dietary essential fatty acids and brain function: a
developmental perspective on mechanisms. Proc Nutr Soc. 2002;61:61–9.
26. Amminger GP, Berger GE, Schäfer MR, Klier C, Friedrich MH, Feucht M.
Omega-3 fatty acids supplementation in children with autism: a
double-blind randomized, placebo-controlled pilot study. Biol
Psychiatry. 2007;61:551–3.
Mostafa and AL-Ayadhi Behavioral and Brain Functions  (2015) 11:4 Page 7 of 727. Politi P, Cena H, Comelli M, Marrone G, Allegri C, Emanuele E, et al.
Behavioral effects of omega-3 fatty acid supplementation in young adults
with severe autism: an open label study. Arch Med Res. 2008;39(7):682–5.
28. Vaz FM, Wanders RJ. Carnitine biosynthesis in mammals. Biochem J.
2002;361:417–29.
29. Slonim AE, Borum PR, Tanaka K, Stanley CA, Kasselberg AG, Greene HL, et al.
Dietary-dependent carnitine deficiency as a cause of nonketotic
hypoglycemia in an infant. J Pediatr. 1981;99:551–5.
30. Vaz FM, Melegh B, Bene J, Cuebas D, Gage DA, Bootsma A, et al. Analysis of
carnitine biosynthesis metabolites in urine by HPLC-electrospray tandem
mass spectrometry. Clin Chem. 2002;48:826–34.
31. Frye RE, Rossignol DA. Mitochondrial dysfunction can connect the diverse
medical symptoms associated with autism spectrum disorders. Pediatr Res.
2011;69:41R–7R.
32. Frye RE, Melnyk S, Macfabe DF. Unique acyl-carnitine profiles are potential
biomarkers for acquired mitochondrial disease in autism spectrum disorder.
Transl Psychiatry. 2013;3:e220.
33. Hatzigiakoumis DS, Martinotti G, Giannantonio MD, Janiri L. Anhedonia and
substance dependence: clinical correlates and treatment options. Front
Psychiatry. 2011;2:10.
34. Chevallier C, Grèzes J, Molesworth C, Berthoz S, Happé F. Brief report:
Selective social anhedonia in high functioning autism. J Autism Dev Disord.
2012;42(7):1504–9.
35. Martinotti G, Reina D, Di Nicola M, Andreoli S, Tedeschi D, Ortolani I, et al.
Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic
alcoholics: a randomized, double-blind, placebo-controlled pilot trial.
Alcohol Alcohol. 2010;45:449–55.
36. Juliet PA, Balasubramaniam D, Balasubramaniam N, Panneerselvam C.
Carnitine: a neuromodulator in aged rats. J Gerontol A Biol Sci Med Sci.
2003;58:970–4.
37. Martinotti G, Andreoli S, Reina D, Di Nicola M, Ortolani I, Tedeschi D, et al.
Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative
symptoms in alcohol dependent subjects. Prog. Neuropsychopharmacol
2011. Biol Psychiatry. 2011;35(4):953–8.
38. Somi MH, Fatahi E, Panahi J, Havasian MR, Judaki A. Data from a
randomized and controlled trial of LCarnitine prescription for the treatment
for Non- Alcoholic Fatty Liver Disease. Bioinformation. 2014;10(9):575–9.
39. Mazefsky CA, Schreiber DR, Olino TM, Minshew NJ. The association between
emotional and behavioral problems and gastrointestinal symptoms among
children with high-functioning autism. Autism. 2013;18:493–501.
40. Macfabe D. Autism: metabolism, mitochondria, and the microbiome. Glob
Adv Health Med. 2013;2:52–66.
41. Macfabe DF. Short-chain fatty acid fermentation products of the gut
microbiome: implications in autism spectrum disorders. Microb Ecol Health
Dis. 2012;23:10.3402/mehd–v23i0.19260.
42. Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora
and gastrointestinal status in children with autism–comparisons to typical
children and correlation with autism severity. BMC Gastroenterol. 2011;11:22.
43. Wehner S, Meder K, Vilz TO, Alteheld B, Stehle P, Pech T, et al. Preoperative
short-term parenteral administration of polyunsaturated fatty acids
ameliorates intestinal inflammation and postoperative ileus in rodents.
Langenbecks Arch Surg. 2012;397:307–15.
44. Babusukumar U, Wang T, McGuire E, Broeckel U, Kugathasan S. Contribution
of OCTN variants within the IBD5 locus to pediatric onset Crohn's disease.
Am J Gastroenterol. 2006;101:1354–61.
45. Akpolat M, Gulle K, Topcu-Tarladacalisir Y, Safi Oz Z, Bakkal BH, Arasli M,
et al. Protection by L-carnitine against radiation-induced ileal mucosal injury
in the rat: pattern of oxidative stress, apoptosis and cytokines. Int J Radiat
Biol. 2013;89:732–40. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
